mycophenolate mofetil

mycophenolate mofetil is an immunosuppressive medication used to prevent organ rejection following transplantation. It is a prodrug of mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, which is crucial for lymphocyte proliferation. The drug is marketed under the brand name CellCept by Hoffmann-La Roche and is also available as a delayed-release formulation called Myfortic.

Medical uses

Mycophenolate mofetil is primarily indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac, or hepatic transplants, typically in combination with ciclosporin and corticosteroids. Its use is supported by major guidelines from organizations like the American Society of Transplantation. Beyond transplantation, it is used off-label in the management of various autoimmune conditions, including lupus nephritis, where it has been shown to be non-inferior to cyclophosphamide in trials like the Aspreva Lupus Management Study. It is also employed in the treatment of conditions such as pemphigus vulgaris, myasthenia gravis, and certain forms of vasculitis, often when patients are intolerant to other agents like azathioprine.

Adverse effects

Common adverse effects include gastrointestinal disturbances such as diarrhea, nausea, and vomiting, which can sometimes necessitate dose reduction or use of the enteric-coated Myfortic. Hematological toxicity, including leukopenia, anemia, and thrombocytopenia, requires regular monitoring of complete blood counts. There is an increased risk of opportunistic infections, notably cytomegalovirus and BK virus infections, and a potentially elevated risk of lymphoproliferative disorders and other malignancies associated with long-term immunosuppression. The drug is Pregnancy Category D due to teratogenic risks and is contraindicated during pregnancy unless no alternative exists.

Pharmacology

Mycophenolate mofetil is a prodrug that is rapidly hydrolyzed in the liver and plasma to its active metabolite, mycophenolic acid. This active form is a potent, selective, non-competitive, and reversible inhibitor of inosine monophosphate dehydrogenase type II, the rate-limiting enzyme in the *de novo* pathway of guanosine nucleotide synthesis. Since T and B lymphocytes are critically dependent on this pathway for proliferation, the drug selectively inhibits their clonal expansion and antibody production. It undergoes glucuronidation in the liver to form the inactive metabolite mycophenolic acid glucuronide, which is primarily excreted in the urine. Significant drug interactions occur with agents like cholestyramine and antacids containing magnesium or aluminum hydroxide, which can reduce its absorption.

History

Mycophenolic acid was first isolated in 1896 by Gosio from a penicillium mold. Its immunosuppressive properties were later investigated in the 1970s and 1980s, notably by researchers at the University of Wisconsin–Madison and the pharmaceutical company Syntex. The development of the mofetil ester prodrug by scientists at Hoffmann-La Roche in the late 1980s significantly improved oral bioavailability. It received approval from the Food and Drug Administration for renal transplantation in 1995, followed by approvals for cardiac transplants in 1998 and hepatic transplants in 2000. Its role expanded following key clinical trials, such as those presented at meetings of the American Society of Nephrology, which established its efficacy in lupus nephritis.

Society and culture

Mycophenolate mofetil is available under several brand names globally, including CellCept and Myfortic. It is on the World Health Organization's List of Essential Medicines. The drug has been the subject of litigation and FDA safety communications regarding its teratogenic potential, leading to stringent risk management programs like the CellCept Risk Evaluation and Mitigation Strategy. Its cost and access have been topics within healthcare systems, including debates in bodies like the National Institute for Health and Care Excellence. The development and marketing of the drug involved significant contributions from the Swiss pharmaceutical industry and have been discussed in forums such as the International Society of Nephrology.

Category:Immunosuppressants Category:Hoffmann-La Roche Category:World Health Organization essential medicines